Zsolt Farkas of Evolut on why today's longevity valuations only work if the winners spend the next decade buying everything ...

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Basecamp Research will train AI models on the world’s largest biological dataset and design new medicines. Most AI ...

Aging Research and Drug Discovery meeting opened with a pitch for prevention and a program building the endpoints the field needs.

One-year results for the open-chest version look promising, the company says, and a catheter-based method is now enrolling ...

Younger founder Christin Glorioso on turning a six-month competition into a side-by-side trial of aging clocks.

Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.

LW-1017, an oral drug that switches the brain’s cleanup system back on, reduced Parkinson’s and Alzheimer’s pathology in aged ...

A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down.

A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...

Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.

Regenerative platforms reach patients on a different clock – our new report explains why, with MuseCell Innovations clearest case in point.